Table S1.
Release kinetics obtained after fitting FB release data from PLGA-NPs-PEG-peptide and PLGA-PEG-peptide NPs into Korsmeyer–Peppas model
| NPs composition | Korsmeyer–Peppas model*
|
Transport mechanism | ||
|---|---|---|---|---|
| r2 | k ± SD (h−n) | n ± SD | ||
| NPs obtained following the scheme indicated in Figure 1A | ||||
| PLGA-NPs-PEG-POD | 0.948 | 7.23±1.32 | 0.47±0.02 | Non-Fickian or anomalous diffusion |
| PLGA-NPs-PEG-HIV-Tat | 0.974 | 2.67±0.07 | 0.63±0.01 | Non-Fickian or anomalous diffusion |
| NPs obtained following the scheme indicated in Figure 1B | ||||
| PLGA-PEG-POD NPs | 0.989 | 2.71±1.48 | 0.60±0.07 | Non-Fickian or anomalous diffusion |
| PLGA-PEG-HIV-Tat NPs | 0.967 | 2.56±0.20 | 0.74±0.11 | Non-Fickian or anomalous diffusion |
Notes: Values are expressed as mean ± SD; n=3
*non-significant differences were observed between POD and HIV-Tat NPs obtained following schemes of Figure 1A and B.
Abbreviations: FB, flurbiprofen; HIV-Tat, human immunodeficiency virus transactivator; k, the release rate constant; n, the diffusion exponent; NPs, nanoparticles; PEG, polyethyleneglycol; PLGA, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; SD, standard deviation.